Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade

Background: Interactions between tumor and microenvironment determine individual response to immunotherapy. Triple negative breast cancer (TNBC) and hepatocellular carcinoma (HCC) have exhibited suboptimal responses to immune checkpoint inhibitors (ICIs). Aspartate beta-hydroxylase (ASPH), an oncofetal protein and tumor associated antigen (TAA), is a potential target for immunotherapy. Methods: Subcutaneous HCC and orthotopic TNBC murine models were established in immunocompetent BALB/c mice with injection of BNL-T3 and 4T1 cells, respectively. Immunohistochemistry, immunofluorescence, H&E, flow cytometry, ELISA and in vitro cytotoxicity assays were performed. Results: The ASPH-MYC signaling cascade upregulates PD-L1 expression on breast and liver tumor cells. A bio-nanoparticle based lambda phage vaccine targeting ASPH was administrated to mice harboring syngeneic HCC or TNBC tumors, either alone or in combination with PD-1 blockade. In control, autocrine chemokine ligand 13 (CXCL13)-C-X-C chemokine receptor type 5 (CXCR5) axis promoted tumor development and progression in HCC and TNBC. Interactions between PD-L1(+) cancer cells and PD-1(+)T cells resulted in T cell exhaustion and apoptosis, causing immune evasion of cancer cells. In contrast, combination therapy (Vaccine+PD-1 inhibitor) significantly suppressed primary hepatic or mammary tumor growth (with distant pulmonary metastases in TNBC). Adaptive immune responses were attributed to expansion of activated CD4(+) T helper type 1 (Th1)/CD8(+) cytotoxic T cells (CTLs) that displayed enhanced effector functions, and maturation of plasma cells that secreted high titers of ASPH-specific antibody. Combination therapy significantly reduced tumor infiltration of immunosuppressive CD4(+)/CD25(+)/FOXP3(+)Tregs. When the PD-1/PD-L1 signal was inhibited, CXCL13 produced by ASPH(+) cancer cells recruited CXCR5(+)/CD8(+)T lymphocytes to tertiary lymphoid structures (TLSs), comprising effector and memory CTLs,T follicular helper cells, B cell germinal center, and follicular dendritic cells. TLSs facilitate activation and maturation of DCs and actively recruit immune subsets to tumor microenvironment. These CTLs secreted CXCL13 to recruit more CXCR5(+) immune cells and to lyse CXCR5(+) cancer cells. Upon combination treatment, formation of TLSs predicts sensitivity to ICI blockade. Combination therapy substantially prolonged overall survival of mice with HCC or TNBC. Conclusions: Synergistic antitumor efficacy attributable to a lambda phage vaccine specifically targeting ASPH, an ideal TAA, combined with ICIs, inhibits tumor growth and progression of TNBC and HCC.

Automated summary

The study found that Aspartate beta-hydroxylase (ASPH) can upregulate the expression of PD-L1 on breast and liver tumor cells through the ASPH-MYC signaling cascade, leading to immune evasion. The combination of a lambda phage vaccine targeting ASPH and PD-1 inhibitors can effectively inhibit the growth and progression of TNBC and HCC, significantly improving the therapeutic effect.